Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,752 shares of the biopharmaceutical company’s stock after acquiring an additional 158 shares during the period. Commonwealth Equity Services LLC’s holdings in Alnylam Pharmaceuticals were worth $1,398,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its position in shares of Alnylam Pharmaceuticals by 572.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 143 shares in the last quarter. Altitude Crest Partners Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter worth $30,000. Robeco Institutional Asset Management B.V. grew its holdings in Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $52,000. Finally, Prestige Wealth Management Group LLC grew its holdings in Alnylam Pharmaceuticals by 69.8% during the 1st quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 194 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Morgan Stanley raised their price target on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a report on Friday, July 12th. Leerink Partners raised their price target on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the company a “market perform” rating in a report on Tuesday, June 25th. UBS Group raised their price target on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a report on Friday, June 28th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, September 4th. Seven analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $279.14.

Alnylam Pharmaceuticals Stock Up 1.4 %

Shares of NASDAQ:ALNY opened at $265.27 on Monday. The company has a market cap of $34.06 billion, a PE ratio of -98.98 and a beta of 0.38. The company’s 50-day moving average price is $258.53 and its 200 day moving average price is $195.09. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to the consensus estimate of $447.22 million. The company’s revenue for the quarter was up 107.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.21) earnings per share. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares of the company’s stock, valued at approximately $20,563,480. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director David E. I. Pyott sold 32,450 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the transaction, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Yvonne Greenstreet sold 15,000 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $20,563,480. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 103,148 shares of company stock valued at $25,658,824. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.